{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:52:56Z","timestamp":1791262376337,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005024","name":"Beijing Postdoctoral Research Foundation","doi-asserted-by":"publisher","award":["2025-zz-19"],"award-info":[{"award-number":["2025-zz-19"]}],"id":[{"id":"10.13039\/501100005024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M772890"],"award-info":[{"award-number":["2025M772890"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZC20251904"],"award-info":[{"award-number":["GZC20251904"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110496","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:20:01Z","timestamp":1789168801000},"page":"110496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Identification of FLT3-ITD inhibitors through AI-guided virtual screening, biochemical validation, DFT analysis, and molecular dynamics simulation"],"prefix":"10.1016","volume":"182","author":[{"given":"Cong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaochun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110496_bb0005","first-page":"379","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.bioorg.2026.110496_bb0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00114-025-02037-4","article-title":"Epidemiology of acute myeloid leukemia in children and adolescents (1990-2021): a global burden of disease study","volume":"112","author":"Jia","year":"2025","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.bioorg.2026.110496_bb0015","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG bio)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bioorg.2026.110496_bb0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/17474086.2024.2356258","article-title":"The potential of triplet combination therapies for patients with FLT3-ITD-mutated acute myeloid leukemia","volume":"17","author":"Bruzzese","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.bioorg.2026.110496_bb0025","first-page":"7","article-title":"Genetic variations in NFKB1 signaling molecules: implications for acute lymphoblastic leukemia in Saudi Arabia","author":"Alkhulaifi","year":"2025","journal-title":"J. Appl. Genet."},{"key":"10.1016\/j.bioorg.2026.110496_bb0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fonc.2020.612880","article-title":"Flt3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.110496_bb0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00277-018-3245-5","article-title":"Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation","volume":"97","author":"Marhall","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bioorg.2026.110496_bb0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-4-13","article-title":"Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110496_bb0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81469-5","article-title":"Switching signals on or off by receptor dimerization","volume":"94","author":"Weiss","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110496_bb0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.bioorg.2026.110496_bb0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/OP.22.00342","article-title":"The cup runneth over: treatment strategies for newly diagnosed acute myeloid leukemia","volume":"19","author":"Cooperrider","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.bioorg.2026.110496_bb0060","first-page":"11","article-title":"Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy","author":"Ge","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bioorg.2026.110496_bb0065","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s11912-025-01709-8","article-title":"Current treatment strategies for FLT3-mutated acute myeloid leukemia in patients not candidates for intensive chemotherapy","volume":"27","author":"Bataller","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bioorg.2026.110496_bb0070","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.leukres.2025.108088","article-title":"Effect of sorafenib on prognosis in patients with low-allelic-ratio FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"157","author":"Yang","year":"2025","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bioorg.2026.110496_bb0075","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.5c00831","article-title":"Discovery of potent dual PROTAC degraders targeting BET-kinase to overcome FLT3 inhibitor resistance","author":"Xiang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110496_bb0080","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110496_bb0085","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1158\/1078-0432.CCR-05-0358","article-title":"CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia","volume":"11","author":"de Menezes","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110496_bb0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.leu.2404508","article-title":"Antitumor activity of sorafenib in FLT3-driven leukemic cells","volume":"21","author":"Auclair","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110496_bb0095","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy) imidazo[2,1-b] [1,3] benzothiazol-2-yl] phenyl} urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110496_bb0100","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bioorg.2026.110496_bb0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110496_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17172931","article-title":"Targeting oncogenic activity and signalling of mutant receptor tyrosine kinase FLT3","volume":"17","author":"Dobrevski","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110496_bb0115","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cells14191526","article-title":"Counter-therapeutic strategies for resistance of FLT3 inhibitors in acute myeloid leukemia","volume":"14","author":"Song","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110496_bb0120","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/cncr.28705","article-title":"Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations","volume":"120","author":"Alvarado","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.110496_bb0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/jm101195a","article-title":"Trends in kinase selectivity insights for target class-focused library screening","volume":"54","author":"Posy","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110496_bb0130","article-title":"Insight into janus kinases specificity: from molecular architecture to cancer therapeutics","volume":"3","author":"Tianhuawei","year":"2024","journal-title":"MedComm Oncol."},{"key":"10.1016\/j.bioorg.2026.110496_bb0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-024-01617-7","article-title":"Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML","volume":"17","author":"Cortes","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110496_bb0140","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","article-title":"Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors","volume":"3","author":"Chang","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.bioorg.2026.110496_bb0145","doi-asserted-by":"crossref","first-page":"21752","DOI":"10.1021\/acs.jmedchem.4c00529","article-title":"Discovery of sila-123 as a highly potent FLT3 inhibitor for the treatment of acute myeloid leukemia with various FLT3 mutations","volume":"67","author":"Wei","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110496_bb0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11864-022-00952-6","article-title":"Which FLT3 inhibitor for treatment of aml?","volume":"23","author":"Senapati","year":"2022","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.bioorg.2026.110496_bb0155","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110496_bb0160","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1021\/acs.jmedchem.8b01714","article-title":"Virtual screening identifies irreversible FMS-like tyrosine kinase 3 inhibitors with activity toward resistance-conferring mutations","volume":"62","author":"Bensinger","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110496_bb0165","doi-asserted-by":"crossref","first-page":"14664","DOI":"10.1021\/acs.jmedchem.1c01196","article-title":"Discovery of a potent FLT3 inhibitor (LT-850-166) with the capacity of overcoming a variety of FLT3 mutations","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110496_bb0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7150\/thno.46593","article-title":"LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia","volume":"11","author":"Yu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.bioorg.2026.110496_bb0175","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/leu.2016.297","article-title":"MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia","volume":"31","author":"Xu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.110496_bb0180","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2013-04-493916","article-title":"G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia","volume":"123","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110496_bb0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2024.216933","article-title":"FLT3-selective PROTAC: enhanced safety and increased synergy with venetoclax in FLT3-ITD mutated acute myeloid leukemia","volume":"592","author":"Tan","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110496_bb0190","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/aoc.7998","article-title":"Design, preparation, characterization, density functional theory, and HOMO-LUMO perspective of Fe3O4@SiO2-PR-NH-IC as a new nanomagnetic chemosensor","volume":"39","author":"Zamiran","year":"2025","journal-title":"Appl. Organomet. Chem."},{"key":"10.1016\/j.bioorg.2026.110496_bb0195","series-title":"Gaussian 16 rev. C.01","author":"Frisch","year":"2016"},{"key":"10.1016\/j.bioorg.2026.110496_bb0200","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"Multiwfn: a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2012","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110496_bb0205","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.bioorg.2026.110496_bb0210","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110496_bb0215","author":"Tian"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826010321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:20:10Z","timestamp":1791260410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826010321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"alternative-id":["S0045206826010321"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110496","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of FLT3-ITD inhibitors through AI-guided virtual screening, biochemical validation, DFT analysis, and molecular dynamics simulation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110496"}}